Inflammation Biomarker Discovery in Parkinson's Disease and Atypical Parkinsonisms

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2020 Jan 19

PMID 31952511

Citations 35

Authors

Anna Santaella

H Bea Kuiperij

Anouke van Rumund

Rianne A J Esselink

Alain J van Gool

Bastiaan R Bloem

Marcel M Verbeek

Affiliations

Soon will be listed here.

Abstract

Background: Parkinson's disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression.

Methods: CSF from a longitudinal cohort study consisting of PD and APD patients (PD, n = 44; multiple system atrophy (MSA), n = 14; vascular parkinsonism (VaP), n = 9; and PD with VaP, n = 7) and controls (n = 25) were analyzed.

Results: Concentrations of CCL28 were elevated in PD compared to controls (p = 0.0001). Five other biomarkers differentiated both MSA and PD from controls (p < 0.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (β-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both p = 0.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho > 0.650; p < 0.01).

Conclusions: PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.

Citing Articles

Integrative Analysis of Metabolome and Proteome in the Cerebrospinal Fluid of Patients with Multiple System Atrophy.

George N, Kwon M, Jang Y, Kim S, Hwang J, Lee S Cells. 2025; 14(4).

PMID: 39996738 PMC: 11853536. DOI: 10.3390/cells14040265.

Comparative Blood Profiling Based on ATR-FTIR Spectroscopy and Chemometrics for Differential Diagnosis of Patients with Amyotrophic Lateral Sclerosis-Pilot Study.

Tkachenko K, Gonzalez-Saiz J, Calvo A, Lunetta C, Osta R, Pizarro C Biosensors (Basel). 2024; 14(11).

PMID: 39589985 PMC: 11591577. DOI: 10.3390/bios14110526.

Proximity Elongation Assay and ELISA for the Identification of Serum Diagnostic Biomarkers in Parkinson's Disease and Progressive Supranuclear Palsy.

Cristiani C, Calomino C, Scaramuzzino L, Murfuni M, Parrotta E, Bianco M Int J Mol Sci. 2024; 25(21).

PMID: 39519214 PMC: 11546529. DOI: 10.3390/ijms252111663.

Growth Factors and Their Application in the Therapy of Hereditary Neurodegenerative Diseases.

Issa S, Fayoud H, Shaimardanova A, Sufianov A, Sufianova G, Solovyeva V Biomedicines. 2024; 12(8).

PMID: 39200370 PMC: 11351319. DOI: 10.3390/biomedicines12081906.

Exploring Fecal Microbiota Transplantation for Modulating Inflammation in Parkinson's Disease: A Review of Inflammatory Markers and Potential Effects.

Sadowski K, Zajac W, Milanowski L, Koziorowski D, Figura M Int J Mol Sci. 2024; 25(14).

PMID: 39062985 PMC: 11277532. DOI: 10.3390/ijms25147741.

References

Hoglinger G, Respondek G, Stamelou M, Kurz C, Josephs K, Lang A . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017; 32(6):853-864. PMC: 5516529. DOI: 10.1002/mds.26987. View

Postuma R, Berg D, Adler C, Bloem B, Chan P, Deuschl G . The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurol. 2016; 15(6):546-8. DOI: 10.1016/S1474-4422(16)00116-2. View

Yoon J, Ann E, Kim M, Ahn J, Jo E, Lee H . Parkin mediates neuroprotection through activation of Notch1 signaling. Neuroreport. 2017; 28(4):181-186. DOI: 10.1097/WNR.0000000000000726. View

Fang F, Wirdefeldt K, Jacks A, Kamel F, Ye W, Chen H . CNS infections, sepsis and risk of Parkinson's disease. Int J Epidemiol. 2012; 41(4):1042-9. PMC: 3429872. DOI: 10.1093/ije/dys052. View

Fardell C, Zettergren A, Ran C, Belin A, Ekman A, Sydow O . S100B polymorphisms are associated with age of onset of Parkinson's disease. BMC Med Genet. 2018; 19(1):42. PMC: 5848451. DOI: 10.1186/s12881-018-0547-3. View

Herbert M, Eeftens J, Aerts M, Esselink R, Bloem B, Kuiperij H . CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat Disord. 2013; 20(1):112-5. DOI: 10.1016/j.parkreldis.2013.09.003. View

Zijlmans J, Daniel S, Hughes A, Revesz T, Lees A . Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord. 2004; 19(6):630-40. DOI: 10.1002/mds.20083. View

Athauda D, Maclagan K, Skene S, Bajwa-Joseph M, Letchford D, Chowdhury K . Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017; 390(10103):1664-1675. PMC: 5831666. DOI: 10.1016/S0140-6736(17)31585-4. View

Grimes D, Han F, Panisset M, Racacho L, Xiao F, Zou R . Translated mutation in the Nurr1 gene as a cause for Parkinson's disease. Mov Disord. 2006; 21(7):906-9. DOI: 10.1002/mds.20820. View

10.

Yamamoto S, Schulze K, Bellen H . Introduction to Notch signaling. Methods Mol Biol. 2014; 1187:1-14. DOI: 10.1007/978-1-4939-1139-4_1. View

11.

Ross G, Petrovitch H, Abbott R, Nelson J, Markesbery W, Davis D . Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol. 2004; 56(4):532-9. DOI: 10.1002/ana.20226. View

12.

Vandivort T, Birkland T, Domiciano T, Mitra S, Kavanagh T, Parks W . Stromelysin-2 (MMP-10) facilitates clearance and moderates inflammation and cell death following lung exposure to long multiwalled carbon nanotubes. Int J Nanomedicine. 2017; 12:1019-1031. PMC: 5304974. DOI: 10.2147/IJN.S123484. View

13.

Tufekci K, Meuwissen R, Genc S, Genc K . Inflammation in Parkinson's disease. Adv Protein Chem Struct Biol. 2012; 88:69-132. DOI: 10.1016/B978-0-12-398314-5.00004-0. View

14.

Glass C, Saijo K, Winner B, Marchetto M, Gage F . Mechanisms underlying inflammation in neurodegeneration. Cell. 2010; 140(6):918-34. PMC: 2873093. DOI: 10.1016/j.cell.2010.02.016. View

15.

van Dijk K, Teunissen C, Drukarch B, Jimenez C, Groenewegen H, Berendse H . Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol Dis. 2010; 39(3):229-41. PMC: 7126274. DOI: 10.1016/j.nbd.2010.04.020. View

16.

Lee H, James W, Cowley S . LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease. Biochem Soc Trans. 2017; 45(1):131-139. PMC: 5652224. DOI: 10.1042/BST20160262. View

17.

Chen L, Mo M, Li G, Cen L, Wei L, Xiao Y . The biomarkers of immune dysregulation and inflammation response in Parkinson disease. Transl Neurodegener. 2016; 5(1):16. PMC: 5002148. DOI: 10.1186/s40035-016-0063-3. View

18.

Lee W, Liao Y, Wang Y, Lin I, Wang S, Fuh J . Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer's Disease and Mild Cognitive Impairment: A Two-year Follow-up Study. Sci Rep. 2018; 8(1):1280. PMC: 5775300. DOI: 10.1038/s41598-018-19807-y. View

19.

Liu J, Cao X, Liu Y, Tang F . CCL28 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus. Neurochem Int. 2012; 61(7):1094-101. DOI: 10.1016/j.neuint.2012.08.001. View

20.

Magdalinou N, Paterson R, Schott J, Fox N, Mummery C, Blennow K . A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015; 86(11):1240-7. PMC: 4564944. DOI: 10.1136/jnnp-2014-309562. View